US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis - Editorial response

被引:42
作者
Berman, JD [1 ]
机构
[1] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Expt Therapeut, Washington, DC 20307 USA
关键词
D O I
10.1086/515086
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:49 / 51
页数:3
相关论文
共 11 条
[11]   Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients [J].
Walsh, TJ ;
Yeldandi, V ;
McEvoy, M ;
Gonzalez, C ;
Chanock, S ;
Freifeld, A ;
Seibel, NI ;
Whitcomb, PO ;
Jarosinski, P ;
Boswell, G ;
Bekersky, I ;
Alak, A ;
Buell, D ;
Barret, J ;
Wilson, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2391-2398